Eliem Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc. is a US-listed biotechnology company on the NASDAQ market in the United States. Founded in 2018 and publicly listed in 2021, the company initially built its identity around therapies for neuronal excitability disorders, targeting unmet medical needs in chronic pain, epilepsy, psychiatry-related conditions, and other disorders of the peripheral and central nervous systems. For investors, the key point is that Eliem underwent a major strategic transformation in 2024: after acquiring Tenet Medicines, it changed its corporate name to Climb Bio, while remaining the same legal and public reporting entity. Its current strategic focus is now on immune-mediated and autoimmune diseases. From an historical perspective, Eliem was incorporated in Delaware in 2018 and operated with roots in Seattle and Cambridge, UK. Its earlier pipeline included assets such as ETX-810, ETX-155, and a Kv7.2/3 program. Over time, however, those programs were reprioritized, paused, or reworked as management adapted the portfolio to clinical and capital-markets realities. In 2024, the company shifted decisively toward immunology after completing the acquisition of Tenet Medicines and advancing budoprutug, previously referred to as TNT119. Budoprutug is an anti-CD19 monoclonal antibody intended for a broad set of B-cell mediated and autoimmune indications, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. Competitively, this remains a small-cap clinical-stage biotech with the classic profile of high scientific optionality and elevated execution risk. Its market position is defined less by current revenues than by pipeline quality, differentiated mechanism of action, and the ability to fund expensive clinical development through inflection points. It competes against larger biopharma companies and specialized biotech peers active in autoimmune disease, especially those pursuing CD19-based or B-cell–targeted approaches. As a result, clinical readouts, regulatory milestones, and capital allocation discipline are central to the investment case. Geographically, the company was originally associated with Seattle and Cambridge, but in 2024 it relocated its corporate headquarters to Massachusetts and now operates from Wellesley Hills. Recent milestones include the closing of the Tenet Medicines acquisition on June 27, 2024, alongside a $120 million private placement. Management indicated that the transaction left the combined company with roughly $220 million in cash and cash equivalents expected to fund operations into 2027. For investors tracking SEC Form 4 insider activity, this strategic reset is especially important because it materially changed the company’s pipeline, financing profile, and long-term narrative.